Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by mjn797979on Dec 01, 2020 5:54pm
106 Views
Post# 32014775

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Antibe update

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Antibe update The realisation this year is that his will take a very very long time to play out.
Very long.
This is gonna trade in this range for minimum 5 years.

The market sees this and absolutely hates it. They had cash bought something in Brazil that the market hated even more.

The price action this year is a clear message. This is dead money, for the foreseeable future.

The smart investors, unfortunately I did not pull trigger on the swing up to 8$, if they sold and invested in tech this summer, made a killing.

I really think we won't see 10$ or even 8$ for a few years.
This Brazil story has to play out, a country ravaged by a pandemic with a President that refuses to even take the vaccine.
Next election there are in 2022.
In the meantime, we wait, our cash depreciates and hope that past success will lead to future success.


<< Previous
Bullboard Posts
Next >>